Analysis Published: August 2000 CD18 trials disappoint again Alan Dove Nature Biotechnology 18, 817–818 (2000) Cite this article ...

Objectives Atherosclerosis (AS) is an inflammatory disease. CD11b/CD18 integrins on PMNs and endothelial cell intercellular adhesion molecule-1 (ICAM-1) mediate PMN adhesion to VECs, resulting in ...

Research Article Published: 11 April 2002 Retroinfusion of NFκB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and ...

Background: Interleukin-2 (IL-2) is a lymphocyte-activating and growth-promoting factor, and has been widely studied on T-cells and NK-cells. However, the interaction of polymorphonuclear neutrophils ...

Anti-CD18 antibodies reduce migration of monocytes across unstimulated human umbilical vein EC monolayers by ≈75%. 26 However, when human umbilical vein EC monolayers are pretreated with ...

Methods and Results —We studied the effect of pretreatment with a monoclonal antibody directed against the CD18 subunit of PMNL β 2 -integrin on the synthesis of cys-LT in a PMNL-perfused isolated ...

The anti-CD18 mAb alone did not significantly alter the phagocytosis of melanized yeast cells, which suggests that cooperation with other receptors is important. Once the microorganisms are ...

When CD18 hypomorphism was partially rescued by reconstitution with the wild-type bone marrow, the resistance of the tumors to irradiation was restored. Our study thus supports the rationale of using ...

Neutrophils are key players in innate immunity and originate from the bone marrow of the adult mammalian organism. In mammals, mature neutrophils are released from the bone marrow into the peripheral ...

Neutrophil accumulation in the intestine was essentially blocked by anti-CD18, and partially blocked by either anti-CD11a or CD11b antibody treatment. Migration into the intestinal lumen was reduced ...